Pharma BD Deal Intelligence

Gilead Sciences, Inc. / Calistoga Pharmaceuticals, Inc.

2011 · Acquisition/Merger · $600M · Complete

Gilead acquired Calistoga for $375M upfront plus up to $225M in milestones. Lead asset CAL-101 (idelalisib) was an oral PI3K-delta inhibitor in clinical development for B-cell malignancies; later approved as Zydelig in 2014.

Did it work? Outcome assessment

Assessment window: 10yr post-close.

Key facts

• Announced Feb 22, 2011
• Closed Apr 01, 2011
• Deal value $600M
• Deal type Acquisition/Merger
• Therapeutic area Hematologic malignancies (CLL, iNHL)
• Indications Hematologic malignancies (CLL, iNHL)
• Key assets CAL-101 (idelalisib)
• Mechanism Selective PI3K-delta inhibitor

← Browse all deals  ·  How we score deals